Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

Maria Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G. Berdeja, Andrzej Jakubowiak, A. Keith Stewart, Sundar Jagannath, Yi Lin, Joris Diels, Francesca Ghilotti, Pushpike Thilakarathne, Nolen J. Perualila, Jedelyn Cabrieto, Benjamin Haefliger, Nichola Erler-Yates, Clare Hague, Carolyn C. Jackson, Jordan M. Schecter, Vadim Strulev, Tonia NesheiwatLida Pacaud, Hermann Einsele, Philippe Moreau

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice'. Together they form a unique fingerprint.

Medicine & Life Sciences